Stifel maintains hold rating and $71 target on Scotts Miracle-Gro stock

Stifel analysts reiterated a Hold rating on Scotts Miracle-Gro (SMG) with a $71 price target, citing concerns about the pace of U.S. Consumer revenue growth for fiscal year 2025 and below-consensus fiscal year 2026 estimates, despite recent upward earnings revisions from other analysts and the company reaffirming its fiscal year 2025 guidance with reduced interest expense projections; this contrasts with Truist Securities' Buy rating and $75 price target, reflecting a mixed outlook on SMG's near-term performance.

Analysis

Scotts Miracle-Gro (SMG) presents a mixed investment landscape, characterized by Stifel's reiterated Hold rating and $71.00 price target, which stem from concerns over the pace of U.S. Consumer revenue growth for fiscal year 2025 and fiscal year 2026 estimates that are significantly below consensus. This cautious outlook from Stifel, reflecting perceived balanced risk/reward, contrasts with SMG's recent stock appreciation of 13.45% over the past week to $65.55 and the company’s reaffirmation of its full fiscal year 2025 guidance. SMG's guidance highlights positive factors such as an expected $30 million reduction in interest expenses and a smaller-than-anticipated increase in diluted share count, alongside continued growth in consumer point-of-sale metrics. The divergence in analyst sentiment is further underscored by Truist Securities maintaining a Buy rating with a $75 price target, optimistic about the confirmed guidance, while UBS holds a Neutral rating with a $54 price target, awaiting more clarity on fiscal year 2026 margin expansion and earnings growth. Adding to the complexity, InvestingPro data reveals that three analysts have recently revised earnings estimates upward for SMG, with net income projected to grow this year, though Stifel's apprehension regarding the quality of FY2025 results and longer-term growth prospects warrants careful consideration.

Key Decisions for Investors

• Investors should weigh Scotts Miracle-Gro's reaffirmed positive FY25 guidance and recent strong stock performance against Stifel's specific concerns regarding the sustainability of U.S. Consumer revenue growth and its below-consensus FY26 estimates.
• Given the mixed analyst ratings and a broad price target range for SMG ($54-$90), with the stock currently trading at $65.55, carefully assess individual risk tolerance and investment horizon, particularly noting Stifel's significantly below-consensus FY26 estimates.
• Monitor upcoming earnings reports for tangible progress in U.S. Consumer segment performance and clarity on FY2026 margin expansion, which will be critical in validating either the company's optimistic outlook or the more cautious analyst views.